Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 15/20 | 0.44 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA9 | Q16790 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383854 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL4957282 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384419 | 0.97 | FAAH (0.48) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL29800472 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384418 | 0.97 | FAAH (0.48) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL2329989 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL575976 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL1239007 | 0.97 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384367 | 0.95 | FAAH (0.52) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384362 | 0.95 | FAAH (0.52) | FAAHCA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306400-A1 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. | HENRI JOHN T | 2009-12-10 | — | — | US | claimed |
| EP-2007739-A2 | A CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES | Tapestry Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007126893-A2 | A CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES | TAPESTRY PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070225510-A1 | Convergent Process for the Synthesis of Taxane Derivatives | TAPESTRY PHARMACEUTICALS, INC. | 2007-09-27 | — | — | US | claimed |
| US-20040186123-A1 | Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline | WYETH | 2004-09-23 | — | — | US | claimed |
| EP-0876388-B1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2004-02-18 | — | — | EP | claimed |
| US-6693197-B2 | Process for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino- [2,3-f] quinoline | WYETH | 2004-02-17 | — | — | US | claimed |
| EP-1387845-A2 | PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-(2,3-f) QUINOLINE | Wyeth (US) | 2004-02-11 | — | — | EP | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020187983-A1 | Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline | WYETH | 2002-12-12 | — | — | US | claimed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0876388-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | claimed |
| US-5817877-A | Metal-catalyzed amination of organic sulfonates to organic amines | YALE UNIVERSITY (US) | 1998-10-06 | — | — | US | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997017356-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-05-15 | — | — | WO | claimed |
| US-4461728-A | Preparation of 4-phenyl-1,3-benzodiazepins | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1984-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225510-A1 | Convergent Process for the Synthesis of Taxane Derivatives | DHPS, TSN, EIF5B | FAAH 3726/4885CA2 4409/4885CA1 2922/4885 |
| US-20020187983-A1 | Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline | CYP1A1, CYP2F1, CYP1B1 | FAAH 2013/4885CA2 2223/4885CA1 1999/4885 |
| US-20090306400-A1 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. | DHPS, TSN, PARP15 | FAAH 3820/4885CA2 4465/4885CA1 3147/4885 |
| US-20040186123-A1 | Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline | CYP1A1, CYP2F1, CYP1B1 | FAAH 2013/4885CA2 2223/4885CA1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.